Filing Flows › Arrowhead Pharmaceuticals (ARWR) › Q3 FY25
Arrowhead Pharmaceuticals (ARWR) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Aug 7, 2025
Arrowhead Pharmaceuticals (ARWR) reported revenue of $27.8M for the third quarter fiscal 2025 (Q3 FY25) and -95% from the quarter before. Operating margin was -596.2%, net loss $179M (643.4% of revenue).
Arrowhead Pharmaceuticals, Q3 FY25: revenue $27.8M, operating margin -596.2%, net loss $179M, operating cash flow −$155M. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $27.8M | -95% | — |
| Operating profit | −$166M | -143% | — |
| Net earnings | −$179M | -148% | — |
| Operating cash flow | −$155M | -134% | — |
What changed
Revenue was $27.8M in Q3 FY25, down 95% from the previous quarter.
Operating costs exceeded revenue by $165.6M, an operating margin of -596.2%. The quarter ended with a net loss of $178.7M, after a profit of $367.9M the previous quarter. Minority interests bore $3.4M of it: to shareholders the quarter was a loss of $175.2M.
Operating cash flow was −$154.7M. Non-cash charges added back $5.8M of depreciation and amortization and $13.0M of share-based compensation. Capital expenditures of $2.4M exceeded it, leaving free cash flow of −$157.1M.
Questions
What was Arrowhead Pharmaceuticals' revenue in the third quarter fiscal 2025?
Arrowhead Pharmaceuticals (ARWR) reported revenue of $27.8M for the third quarter fiscal 2025 (Q3 FY25) and -95% from the quarter before.
Was Arrowhead Pharmaceuticals profitable in the third quarter fiscal 2025?
Operating loss was $166M (-596.2% of revenue) and net loss $179M.